Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 5, 1998, Pages 391-399

  Mullany, Sally ^a   Svingen, Phyllis A ^a   Kaufmann, Scott H ^a,b   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Colon cancer; Deoxynucleotide pools; Fluoropyrimidines; Irinotecan; Thymidylate synthase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; THYMIDINE TRIPHOSPHATE;

ARTICLE; CELL CYCLE; COLONY FORMATION; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOTOXICITY; DNA SYNTHESIS; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INTESTINE CARCINOMA; MICROFLUOROMETRY; PRIORITY JOURNAL; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL CYCLE; CELL SURVIVAL; DEOXYURACIL NUCLEOTIDES; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FLUOROURACIL; HUMANS; INTESTINAL NEOPLASMS; LEUCOVORIN; THYMIDYLATE SYNTHASE; THYMINE NUCLEOTIDES; TUMOR CELLS, CULTURED;

EID: 0031684654     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050835     Document Type: Article

References (46)

1. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896
2. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M, Rougier P (1995) CPT-11 (Irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283
3. Berenbuum MC (1989) What is synergy? Pharmacol Rev 41: 93
4. Bible K, Kaufmann SH (1997) Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: importance of sequence of administration. Cancer Res 57: 3375
5. Chang J-Y, Dethlefsen LA, Barley LR, Zhou BS, Cheng Y-C (1992) Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 43: 2443
6. Chen AY, Liu LF (1994) DNA Topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191
7. Chou T-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27
8. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou T-C, Sun M, Pulliam S, Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709
9. Erlichman C, Svingen PA, Mullany SA, Kaufmann SH (1996) Synergistic interaction of SN-38 and 5FU/leucovorin. Proc Am Assoc Cancer Res 37: 294
10. Fonseca R, Goldberg RM, Erlichman C, Kaufmann SH, Sloan JA, Miller LL (1997) Phase I study of CPT-11/5FU/leucovorin. Proc Am Assoc Cancer Res 38: 76
11. Froelich-Ammon SJ, Osheroff N (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270: 21429
12. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331
13. Grem JL (1996) 5-Fluoropyrimidines: In: Chabner BA, Longo DL (eds) Cancer Chemotherapy and Biotherapy. Lippincott-Raven Publishers, Philadelphia, Second, p 149
14. Grossin F, Barbault H, Benhammouda A, Rixe O, Antoine E, Auclerc G, Weil M, Nizri D, Farabos C, Mignard D, Mahjoubi M, Khayat D, Bastian G (1996) A phase I pharmacokinetics study of concomitant CPT-11 (C) and 5FU (F) combination. Proc Am Assoc Cancer Res 37: 168
15. Guichard MJ, Caliaro G, Houin R, Bugat P, Canal P (1996) Sequential exposure to CPT-11 and 5FU is synergistic in human colon carcinoma HT-29 cell line. Proc Am Assoc Cancer Res 37: 292
16. Hanauske A-R (1993) In vitro assays for antitumour activity: more pitfalls to come? Eur J Cancer 29A: 1502
17. Houghton JA, Tillman DM, Harwood FG (1995) Ratio of 2′-deoxyadenosine-5′-triphosphate/thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res 1: 723
18. Jackson RC (1978) The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of amethopterin, 5-fluorodeoxyuridine, and 3-deazauridine. J Biol Chem 253: 7440
19. Johnston PG, Liang C-M, Henry S, Chabner BA, Allegra CJ (1991) Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 51: 6668
20. Kano Y, Suzuki K, Akutau M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604
21. Kaufmann SH (1989) Additional members of the rat liver lamin polypeptide family: structural and immunological characterization. J Biol Chem 264: 13946
22. Kaufmann SH, McLaughlin SJ, Kastan M, Liu LF, Karp JE, Burke PJ (1991) Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 51: 3534
23. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ (1994) Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83: 517
24. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Donehower RC, Rowinsky EK (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734
25. Leichman CG, Fleming TR, Muggia FM, Tangen CM (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 13: 1303
26. Mans DR, Brondani da Rocha A, Vargas Schwartzbold C, Schwartsmann G (1996) Assessment of the efficacy of the irinotecan (CPT-11)/5-fluorouracil (5-FU) combination in a panel of human colon carcinoma cell lines. Proc Am Assoc Cancer Res 37: 291
27. Moertel CG (1994) Chemotherapy for colorectal cancer. N Engl Med 330: 1136
28. Nelson WG, Kastan MB (1994) DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815
29. Pagliacci MC, Spinozzi F, Migliorati G, Fumi G, Smacchia M, Grignani F, Riccardi C, Nicoletti I (1993) Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer 29 A: 1573
30. Parnes HL, Tait N, Conley B, Van Echo D (1995) A phase 1 study of CPT-11, weekly bolus 5-FU and leucovorin in patients with metastataic cancer. Oncol Rep 2: 1131
31. Potmesil M (1994) Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431
32. Pressacco J, Hedley DW, Erlichman C (1994) ICI D1694 and idoxuridine: a synergistic antitumor combination. Cancer Res 54: 3772
33. Rode W, Scanlon KJ, Moroson BA, Bertino JR (1980) Regulation of thymidylate synthetase in mouse leukemia cells (L1210). J Biol Chem 255: 1305
34. Rothenberg ML, Eckardt JR, Kuhn JG, B, HA Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG. Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128
35. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427
36. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14: 2959
37. Sasaki Y, Ohtsu A, Shimada Y, Ono K, Saijo N (1994) Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 86: 1096
38. Shimada Y, Sasaki Y, Sugano K, Shirao K, Kondo H, Yokota T, Saito D, Tamura T, Ohe Y, Shinkai T (1993) Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 12: 196
39. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271
40. Snapka RM, Permana PA (1993) SV40 DNA replication intermediates: analysis of drugs which target mammalian DNA replication. Bioessays 15: 121
41. 2. Nature 254: 245
42. Tompkins WAF, Watrach AM, Schmale JD, Harris JA (1974) Cultural and antigenic properties of newly established cell strains derived from adenocarcinomas of the human colon and rectum. J Natl Cancer Inst 52: 1101
43. Tsao YP, D'Arpa P, Liu L (1992) The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of P34cdc2/cyclin B1. Cancer Res 52: 1823
44. Yalowich JC, Kalman TI (1985) Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem Pharmacol 34: 2319
45. Yamao T, Shimada Y, Shirao K, Kondo H, Matsumura Y, Sugano K, Saito D, Ohtsu A, Boku N, Yoshida S, Sasaki Y, Ono K (1996) Phase I study of CPT-11 combined with sequential 5FU in metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 15: 481
46. Zeghari-Squalli N, Misset JL, Goldwasser F (1997) Mechanism of the in vitro interaction between SN38 and 5-FU (abstract). Proc Am Assoc Cancer Res 38: 19